南新制药
(688189)
| 流通市值：25.60亿 | | | 总市值：25.60亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 26,048,842.59 | 141,927,557.53 | 83,154,434.61 | 61,846,347.67 |
| 营业收入 | 26,048,842.59 | 141,927,557.53 | 83,154,434.61 | 61,846,347.67 |
| 二、营业总成本 | 37,949,700.94 | 221,773,704.15 | 138,946,104.66 | 93,637,777.93 |
| 营业成本 | 19,480,828.64 | 97,215,784.79 | 55,348,509.22 | 36,563,058.1 |
| 税金及附加 | 566,182.02 | 2,430,517.94 | 1,820,173.75 | 1,291,448.89 |
| 销售费用 | 5,358,199.06 | 46,912,591.9 | 24,541,835.55 | 18,023,006.09 |
| 管理费用 | 8,443,187.03 | 39,771,992.31 | 30,887,241.66 | 21,211,408.14 |
| 研发费用 | 4,255,935.1 | 35,357,159.29 | 27,300,905.81 | 17,554,291.71 |
| 财务费用 | -154,630.91 | 85,657.92 | -952,561.33 | -1,005,435 |
| 其中:利息费用 | 44,870.73 | 3,575,685.32 | 2,223,516.64 | 1,448,716.65 |
| 其中:利息收入 | 217,649.47 | 3,546,400.08 | 3,254,491.46 | 2,521,816.33 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | -4,366,052.08 | -275,386.3 |
| 资产处置收益 | - | 2,526,385.47 | 2,228,555.38 | 1,799,150.21 |
| 资产减值损失(新) | 330,366.66 | -41,539,582.46 | -4,848,544.02 | -3,555,852.62 |
| 信用减值损失(新) | -3,834,634.92 | -15,235,532.35 | -14,482,340.33 | -10,528,947.5 |
| 其他收益 | 300,667.47 | 1,516,064.24 | 1,303,971.03 | 399,934.48 |
| 四、营业利润 | -15,104,459.14 | -132,578,811.72 | -75,956,080.07 | -43,952,531.99 |
| 加:营业外收入 | - | 4,996.22 | 9,378.1 | 313.45 |
| 减:营业外支出 | 3,130.72 | 171,778.36 | 171,598.96 | 16,395.96 |
| 五、利润总额 | -15,107,589.86 | -132,745,593.86 | -76,118,300.93 | -43,968,614.5 |
| 减:所得税费用 | -307,420.12 | 17,009,184.77 | -341,011.36 | -142,099.2 |
| 六、净利润 | -14,800,169.74 | -149,754,778.63 | -75,777,289.57 | -43,826,515.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -14,800,169.74 | -149,754,778.63 | -75,777,289.57 | -43,826,515.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -13,243,582.08 | -136,900,385.31 | -68,633,808.25 | -40,002,316.74 |
| 少数股东损益 | -1,556,587.66 | -12,854,393.32 | -7,143,481.32 | -3,824,198.56 |
| 扣除非经常损益后的净利润 | -13,452,272.29 | -138,339,053.65 | -66,491,537.94 | -41,731,433.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | -0.5 | -0.25 | -0.15 |
| (二)稀释每股收益 | -0.05 | -0.5 | -0.25 | -0.15 |
| 九、综合收益总额 | -14,800,169.74 | -149,754,778.63 | -75,777,289.57 | -43,826,515.3 |
| 归属于母公司股东的综合收益总额 | -13,243,582.08 | -136,900,385.31 | -68,633,808.25 | -40,002,316.74 |
| 归属于少数股东的综合收益总额 | -1,556,587.66 | -12,854,393.32 | -7,143,481.32 | -3,824,198.56 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |